Mesoblast Limited
MESO
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.2B
$17.32
▲ +1.05%
P/E
-47.19
Mkt Cap
$2.2B
52-Wk Range
$13.05–$21.50
52-Week Range
$13.05 - $21.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 19.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+25.5% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying MESO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 26, 2026
Reported EPS of -$0.13 vs -$0.11 consensus (-23.2% surprise). Revenue of $69.0M vs $67.0M expected (+3.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-23.2%
Revenue trend · last 3Q
—
—
+391%
Q1 26
Q2 26
Q4 26
$25.7M
$25.7M
$34.5M
Margins · last 3Q
Gross
—
Operating
-59.5%
Profit
-25.2%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Aug 27, 2026
vs Industry
How MESO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.